Mesenchymal stromal cell therapy: Progress to date and future outlook

Area of Science:

• Regenerative Medicine
• Cell Therapy
• Clinical Trials

Background:

• Mesenchymal stromal/stem cells (MSCs) have a well-established safety profile in clinical investigations.
• Despite safety, MSCs have shown inconsistent efficacy, leading to numerous trial failures and limited regulatory approvals.
• A recent U.S. FDA approval for pediatric graft-vs.-host disease marks a significant milestone for MSC therapy.

Purpose of the Study:

• To review the history and therapeutic potential of MSCs.
• To provide an overview of currently approved MSC products and registered clinical trials.
• To discuss unresolved challenges and future directions for MSC therapy.

Main Methods:

• Literature review of MSC history and therapeutic value.
• Analysis of regulatory-approved MSC products.
• Summary of clinical trials registered on clinicaltrials.gov.
• Discussion of current challenges and future research needs.

Main Results:

• MSCs are safe but efficacy demonstration has been inconsistent across trials.
• Limited MSC therapies have received regulatory approval globally.
• One MSC therapy is now approved by the U.S. FDA for pediatric graft-vs.-host disease.

Conclusions:

• While MSCs are safe, inconsistent efficacy remains a major hurdle for clinical application.
• Further research is needed to overcome challenges and enable routine clinical use of MSCs.
• The recent FDA approval signifies progress but highlights the need for continued investigation.